Document is current
Any future updates will be listed below
-
Authors
De Groof, Timo W. M. https://orcid.org/0000-0001-6918-2955
Elder, Elizabeth G. https://orcid.org/0000-0003-1615-2642
Lim, Eleanor Y.
Heukers, Raimond https://orcid.org/0000-0003-4498-7751
Bergkamp, Nick D.
Groves, Ian J. https://orcid.org/0000-0001-8882-6701
Wills, Mark
Sinclair, John H.
Smit, Martine J. https://orcid.org/0000-0003-2713-0238
-
Funding
Funding for this research was provided by:
Wellcome Trust (grant MR/K021087/1)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Vici grant 016.140.657)
- License Information
-
More Information
Article History
Received: 15 April 2020
Accepted: 17 June 2021
First Online: 21 July 2021
Competing interests
: The authors declare the following competing interests: R.H. is affiliated with QVQ Holding BV, a company offering VHH services and VHH-based imaging molecules. T.D.G, E.E., R.H., J.S., and M.S. are co-inventors on a pending EU patent application EP19190047.1, which covers the use of US28-targeting nanobodies for T-cell-mediated killing of HCMV latently infected cells. The remaining authors declare no competing interests.
